ASCO 2026 preview – Revolution completes its rout

22 April 2026

Daraxonrasib scores a plenary session late-breaker.

Barely a week after the success of Revolution’s daraxonrasib in the Rasolute-302 trial in pancreatic cancer, and the resulting close of a monster $2.2bn financing, the company has scored its third win: Rasolute-302 has secured a late-breaking presentation at the coveted plenary session of next month’s ASCO conference.Given such investor enthusiasm, which has sent Revolution’s valuation above $31bn, the dataset will be scrutinised in depth to see whether it really lives up to its billing as being “transformative”. Meanwhile, AstraZeneca will be a notable absentee from the plenary session, and the double-plenary prize this year has instead gone to Lilly.The subject of all five plenary session late-breakers are now public, with ASCO revealing all presentation titles on Tuesday. The abstract texts remain under wraps until 21 May, while late-breakers won’t be made public until the morning of the day of their presentation at ASCO itself.Pancreatic revolutionRevolution has already revealed some tidbits about Rasolute-302, a study of the pan-RAS inhibitor daraxonrasib in second-line pancreatic cancer, notably that median OS in all comers came in at 13.2 months, versus 6.7 months with chemotherapy (hazard ratio 0.40; p<0.0001).However, the study’s co-primary endpoints are PFS and OS in RAS G12-mutant disease specifically. It would be strange for the result in the G12 subgroup to be worse than in all-comers, but this will remain a key focus, as will the statistical rigour of any result that might back an all-comers filing. With rash earlier looking problematic, toxicity will also be scrutinised. Presentations at ASCO’s plenary sessionProjectMechanismCompanyTrialSettingAbstractNoteErleadaAR inhibitorJohnson & JohnsonProteusNeo(adj) locally advanced prostate cancer, +ADT, vs ADT + surgeryLBA1No data, readout had once been expected in 2024VerzenioCDK4/6 inhibitorLillySarc041Dedifferentiated liposarcoma, vs placeboLBA2No data toplinedRetevmoRET inhibitorLillyLibretto-432Adjuvant RET fusion+ve NSCLCLBA3Toplined positive for EFS in Feb 2026IvonescimabPD-1 x VEGF MAbAkeso/ SummitHarmoni-61st-line NSCLC, +Tevimbra, vs Tevimbra + chemoLBA4PFS data were presented at ESMO 2025DaraxonrasibPan-RAS inhibitorRevolutionRasolute-3022nd-line PDAC, vs SoCLBA5Toplined positive for PFS on 13 Apr 2026Source: ASCO. Lilly’s double plenary concerns Retevmo in adjuvant RET fusion-positive NSCLC, with the recently toplined Libretto-432 study, and Verzenio in the unusual setting of differentiated liposarcoma (Sarc041 trial).Libretto-432 is known to be positive for event-free survival versus chemo, and could expand Retevmo’s reach in lung cancer, where the drug is approved in first-line RET-positive disease; any hints of an OS benefit will also be keenly awaited. Nothing is known about Verzenio’s performance in Sarc041, a study sponsored by Sarcoma Alliance for Research Through Collaboration.Harmoni achievedAnother key plenary late-breaker concerns Akeso’s Harmoni-6 trial of the Summit-partnered anti-PD-1 x VEGF bispecific ivonescimab in front-line NSCLC.That had been toplined positive for PFS a year ago, with full data coming later at ESMO’s presidential session, but ASCO promises to reveal whether PFS has translated into an all-important OS result. Crucially, however, Harmoni-6 is a Chinese not a global trial, and uses Tevimbra as the active combo partner, comparing against Tevimbra plus chemo; the combo ivonescimab realistically needs to beat is Keytruda plus chemo.As such, the main role of Harmoni-6 is to act as a prelude to the overhauled Harmoni-3 study, which does use Keytruda rather than Tevimbra, and is global; interim PFS data from Harmoni-3's squamous cohort are expected in the current quarter. As for Harmoni-6, statistical alpha in this study is known to be split between PFS and OS, necessitating the clearance of a one-sided p value of 0.025, with powering assuming a reduction in risk of death of at least 27%.The final ASCO plenary presentation concerns the Proteus trial of Johnson & Johnson’s Erleada as a perioperative therapy in locally advanced prostate cancer. The drug is approved for metastatic hormone-sensitive, and non-metastatic castration-sensitive disease, but Proteus offers the hope of an even earlier setting; data had earlier been expected in 2024, however.ASCO 2026 takes place in Chicago on 29 May to 2 June.

Given such investor enthusiasm, which has sent Revolution’s valuation above $31bn, the dataset will be scrutinised in depth to see whether it really lives up to its billing as being “transformative”. Meanwhile, AstraZeneca will be a notable absentee from the plenary session, and the double-plenary prize this year has instead gone to Lilly.

The subject of all five plenary session late-breakers are now public, with ASCO revealing all presentation titles on Tuesday. The abstract texts remain under wraps until 21 May, while late-breakers won’t be made public until the morning of the day of their presentation at ASCO itself.

Pancreatic revolution

Revolution has already revealed some tidbits about Rasolute-302, a study of the pan-RAS inhibitor daraxonrasib in second-line pancreatic cancer, notably that median OS in all comers came in at 13.2 months, versus 6.7 months with chemotherapy (hazard ratio 0.40; p<0.0001).

However, the study’s co-primary endpoints are PFS and OS in RAS G12-mutant disease specifically. It would be strange for the result in the G12 subgroup to be worse than in all-comers, but this will remain a key focus, as will the statistical rigour of any result that might back an all-comers filing. With rash earlier looking problematic, toxicity will also be scrutinised.

Presentations at ASCO’s plenary session

Project	Mechanism	Company	Trial	Setting	Abstract	Note
Erleada	AR inhibitor	Johnson & Johnson	Proteus	Neo(adj) locally advanced prostate cancer, +ADT, vs ADT + surgery	LBA1	No data, readout had once been expected in 2024
Verzenio	CDK4/6 inhibitor	Lilly	Sarc041	Dedifferentiated liposarcoma, vs placebo	LBA2	No data toplined
Retevmo	RET inhibitor	Lilly	Libretto-432	Adjuvant RET fusion+ve NSCLC	LBA3	Toplined positive for EFS in Feb 2026
Ivonescimab	PD-1 x VEGF MAb	Akeso/ Summit	Harmoni-6	1st-line NSCLC, +Tevimbra, vs Tevimbra + chemo	LBA4	PFS data were presented at ESMO 2025
Daraxonrasib	Pan-RAS inhibitor	Revolution	Rasolute-302	2nd-line PDAC, vs SoC	LBA5	Toplined positive for PFS on 13 Apr 2026

Source: ASCO.

Lilly’s double plenary concerns Retevmo in adjuvant RET fusion-positive NSCLC, with the recently toplined Libretto-432 study, and Verzenio in the unusual setting of differentiated liposarcoma (Sarc041 trial).

Libretto-432 is known to be positive for event-free survival versus chemo, and could expand Retevmo’s reach in lung cancer, where the drug is approved in first-line RET-positive disease; any hints of an OS benefit will also be keenly awaited. Nothing is known about Verzenio’s performance in Sarc041, a study sponsored by Sarcoma Alliance for Research Through Collaboration.

Harmoni achieved

Another key plenary late-breaker concerns Akeso’s Harmoni-6 trial of the Summit-partnered anti-PD-1 x VEGF bispecific ivonescimab in front-line NSCLC.

That had been toplined positive for PFS a year ago, with full data coming later at ESMO’s presidential session, but ASCO promises to reveal whether PFS has translated into an all-important OS result. Crucially, however, Harmoni-6 is a Chinese not a global trial, and uses Tevimbra as the active combo partner, comparing against Tevimbra plus chemo; the combo ivonescimab realistically needs to beat is Keytruda plus chemo.

As such, the main role of Harmoni-6 is to act as a prelude to the overhauled Harmoni-3 study, which does use Keytruda rather than Tevimbra, and is global; interim PFS data from Harmoni-3's squamous cohort are expected in the current quarter. As for Harmoni-6, statistical alpha in this study is known to be split between PFS and OS, necessitating the clearance of a one-sided p value of 0.025, with powering assuming a reduction in risk of death of at least 27%.

The final ASCO plenary presentation concerns the Proteus trial of Johnson & Johnson’s Erleada as a perioperative therapy in locally advanced prostate cancer. The drug is approved for metastatic hormone-sensitive, and non-metastatic castration-sensitive disease, but Proteus offers the hope of an even earlier setting; data had earlier been expected in 2024, however.

ASCO 2026 takes place in Chicago on 29 May to 2 June.